Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma

Journal of Clinical Oncology

Volumn 19, Issue 10, 2001, Pages 2674-2678

  Acland, K M ^a   Healy, C ^b   Calonje, E ^b   O'Doherty, M ^b   Nunan, T ^b   Page, C ^b   Higgins, E ^b   Russell Jones, R ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; FEMALE; GLUCOSE METABOLISM; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RELIABILITY; SKIN TUMOR;

EID: 0035873999     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.10.2674     Document Type: Article

References (36)

1. Morton DL, Duan-Ren W, Wong JH, et al: Technical details of intraoperative mapping for early stage melanoma. Arch Surg 127:392-399, 1992
2. Biaheta H-J, Ellwanger U, Schittek B, et al: Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma. J Invest Dermatol 114:637-642, 2000
3. Shivers SC, Wang X, Li W, et al: Molecular staging of malignant melanoma: Correlation with clinical outcome. JAMA 280:1410-1415, 1998
4. Gadd MA, Cosimi B, Yu J, et al: Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg 134:381-387, 1999
5. Blessing C, Feine U, Geiger L, et al: Positron emission tomography and ultrasonography. Arch Dermatol 131:1394-1398, 1995
6. Steinert HC, Huch Boni RA, Buck A, et al: Malignant melanoma: Staging with whole body positron emission tomography and 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 195:705-709, 1995
7. Garrison M, Nathanson L: Prognosis and staging in melanoma. Semin Oncol 23:725-733, 1996
8. NIH consensus development panel on early melanoma. JAMA 268:1314-1319, 1992
9. Greigo RD, Zitelli JA: Management of stage 1 malignant melanoma. Dermatol Surg 22:730-735, 1996 (letter)
10. Huang CL, Provost N, Marghoob AA, et al: Laboratory tests and imaging in patients with cutaneous malignant melanoma. J Am Acad Dermatol 39:451-463, 1998
11. Garg R, McPherson TA, Lentle B, et al: Usefulness of an elevated serum lactate dehydrogenase value as a marker of hepatic metastases in malignant melanoma. Can Med Assoc J 120:114-116, 1979
12. Rivers JK: Melanoma. Lancet 347:803-807, 1996
13. Lang PG: Malignant Melanoma. Med Clin Am 82:1325-1358, 1998
14. Terhune MH, Swanson N, Johnson TM: Use of chest radiography in the initial evaluation of patients with localized melanoma. Arch Dermatol 134:569-572, 1998
15. Au FC, Maier WP, Malmud LS, et al: Preoperative nuclear scans in patients with melanoma. Cancer 53:2095-2097, 1984
16. Evans RA, Bland KI, McMurtrey MJ, et al: Radionuclide scans not indicated for clinical stage 1 melanoma. Surg Gynecol Obstet 150:532-534, 1980
17. Khansur T, Sanders J, Das SK: Evaluation of staging workup in malignant melanoma. Arch Surg 124:847-849, 1989
18. Buzaid AC, Sandler AB, Mani S, et al: Role of computed tomography in the staging of primary melanoma. J Clin Oncol 11:638-643, 1993
19. Berman C, Reintgen D: Radiologic imaging in malignant melanoma: A review. Semin Surg Oncol 9:232-238, 1993
20. Bostick PJ, Morton DL, Turner RR, et al: Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early stage melanoma patients. J Clin Oncol 17:3238-3244, 1999
21. Gershenwald JE, Thompson W, Mansfield PF, et al: Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17:976-983, 1999
22. Shivers SC, Wang X, Li W, et al: Molecular staging of malignant melanoma: Correlation with clinical outcome. JAMA 280: 1410-1415, 1998
23. 18F)-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 16:1770-1776, 1998
24. Boni R, Huch Boni RA, Steinen H, et al: Staging of malignant melanoma by whole body positron emission tomography using 2-fluorine-18-fluoro-2-Deoxy-D-glucose. Br J Dermatol 132:556-562, 1995
25. Holder WD, White RL, Zuger JH, et al: Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 227:764-771, 1998
26. 18F-fluorodeoxyglucose positron emission tomography. Cancer 82:1664-71, 1998
27. Gritters LS, Francis IR, Zasadny KR, et al: Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 34:1420-1427, 1993
28. 18F-Fluorodeoxyglucose positron emission tomography. Cancer 82:1664-1671, 1998
29. Wagner JD, Schauwecker D, Hutchins G, et al: Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 64:181-189, 1997
30. Wagner JD, Schauwecker D, Davidson D et al: Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 17:1508-1515, 1999
31. Ross MI, Reitgen DS: Role of lymphatic mapping and sentinel node biopsy in the detection of melanoma nodal metastases. Eur J Cancer 34:S7-S9, 1998 (suppl 3)
32. Morton DL, Duan-Ren W, Wong JH, et al: Technical details of intraoperative mapping for early stage melanoma. Arch Surg 127:392-399, 1992
33. Pijpers R, Collet GJ, Meijer S, et al: The impact of dynamic lymphoscintigraphy and gamma probe guidance on sentinel node biopsy in melanoma. Eur J Nucl Med 22:1238-1241, 1995
34. Krag DN, Meijer SJ, Weaver DL, et al: Minimal-access surgery for staging of malignant melanoma. Arch Surg 130:654-658, 1995
35. Glass LF, Messina JL, Cruse W, et al: The use of radiolymphoscintigraphy for sentinel node biopsy in patients with malignant melanoma. Dermatol Surg 22:715-720, 1996
36. Glass LF, Cottam JA, Reintgen DS, et al: Lymphatic mapping and sentinel node biopsy in the management of high risk melanoma. J Am Acad Dermatol 39:603-610, 1998